ArticleThe Lancet regional health. Southeast Asia2026

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial.

Subhash Thuluva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.